BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0044
+0.0002 (4.76%)
Feb 20, 2025, 2:14 PM CET
-86.25%
Market Cap 2.07M
Revenue (ttm) 2.87M
Net Income (ttm) -7.44M
Shares Out 469.69M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,270,233
Average Volume 8,547,194
Open 0.0046
Previous Close 0.0042
Day's Range 0.0042 - 0.0046
52-Week Range 0.0030 - 0.0360
Beta -2.84
RSI 49.93
Earnings Date Apr 25, 2025

About BioSenic

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult ti... [Read more]

Industry Biotechnology
Sector Healthcare
CEO François Rieger
Country Belgium
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2023, BioSenic's revenue was 543,000, an increase of 104.14% compared to the previous year's 266,000. Losses were -28.78 million, 843.9% more than in 2022.

Financial Statements

News

There is no news available yet.